Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population

January 30, 2026 updated by: Lantarima Bhoopat, Thammasat University

Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis-A Ten Year Retrospective Study.

The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is:

• Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Adult patients aged ≥18 years with histopathological confirmed cancer, treated at Thammasat University Hospital and Panyananthaphikkhu Chonprathan Medical Center between January 2012 and December 2022, were eligible for inclusion.

Patients were initially screened using ICD-10 diagnostic codes C00-D009 for malignancy in conjunction with codes for venous thromboembolism (I82.-, other venous embolism and thrombosis; K55.0, mesenteric vein thrombosis; I82.0, hepatic vein thrombosis; K75.1, phlebitis of the portal vein; and I26.-, pulmonary embolism). Eligible patients required to have a radiologically confirmed diagnosis of cancer-associated thrombosis (CAT) and to have received anticoagulation therapy for at least six months. Clinical data were extracted from the Computerized Provider Order Entry (CPOE) system.

Study Type

Observational

Enrollment (Actual)

169

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients treated at Thammasat University Hospital or Panyananthaphikkhu Chonprathan Medical Center.

Description

Here's a polished version of your Inclusion and Exclusion Criteria section with grammar, spelling, and phrasing corrected for clarity and formal research style:

Inclusion Criteria

  • Adult patients aged ≥18 years
  • Histopathologically confirmed cancer
  • Radiologically confirmed diagnosis of cancer-associated thrombosis (CAT)
  • Received anticoagulation therapy for at least six months Exclusion Criteria
  • Patients who do not meet the inclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Therapeutic dose anticoagulant group
including patients with the standard therapeutic dose-administered after the initial six-month treatment period.
Drug: Anticoagulant
warfarin at therapeutic level (INR 2-3), Low molecular weight heparin (LMWH) DOAC
Prophylactic dose anticoagulant group
including patients with the doses lower than therapeutic dose-administered at any point after the initial six-month treatment period.
Drug: Anticoagulant
warfarin at therapeutic level (INR 2-3), Low molecular weight heparin (LMWH) DOAC

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recurrent thrombosis
Time Frame: After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.
cumulative incidence of recurrent thrombosis
After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anticoagulant related bleeding
Time Frame: After completing 6-month of treatment to the time that anticoagulant stop or bleeding occurred through study completion, at the end of December 2025.
cumulative incidence of bleeding
After completing 6-month of treatment to the time that anticoagulant stop or bleeding occurred through study completion, at the end of December 2025.
Overall survival
Time Frame: The time from VTE diagnosis to last follow up or die through study completion, at the end of December 2025.
Overall survival
The time from VTE diagnosis to last follow up or die through study completion, at the end of December 2025.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Thammasat University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2012

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

December 31, 2025

Study Registration Dates

First Submitted

January 21, 2026

First Submitted That Met QC Criteria

January 30, 2026

First Posted (Actual)

February 4, 2026

Study Record Updates

Last Update Posted (Actual)

February 4, 2026

Last Update Submitted That Met QC Criteria

January 30, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MTU-EC-IM-1-301/65

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer-associated Thrombosis

Clinical Trials on Anticoagulant

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe